Page last updated: 2024-10-27

gabexate and Coronavirus Infections

gabexate has been researched along with Coronavirus Infections in 14 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).

Research Excerpts

Excerpt	Relevance	Reference
"Pretreatment with camostat (0."	1.56	Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. ( Deng, X; Kikuchi, A; Nagatomi, R; Nishimura, H; Yamaya, M, 2020)
"Camostat has been clinically used to treat chronic pancreatitis, and thus represents an exciting potential therapeutic for respiratory coronavirus infections."	1.42	Protease inhibitors targeting coronavirus and filovirus entry. ( Agudelo, J; Barnard, D; Carrion, R; Lu, K; McKerrow, JH; Nunneley, JW; Pöhlmann, S; Renslo, AR; Simmons, G; Vedantham, P; Zhou, Y, 2015)

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (14.29)	24.3611
2020's	12 (85.71)	2.80

Authors

Authors	Studies
Hoffmann, M	1
Kleine-Weber, H	1
Schroeder, S	1
Krüger, N	1
Herrler, T	1
Erichsen, S	1
Schiergens, TS	1
Herrler, G	1
Wu, NH	1
Nitsche, A	1
Müller, MA	1
Drosten, C	1
Pöhlmann, S	2
Henrickson, SE	1
Stopsack, KH	1
Mucci, LA	1
Antonarakis, ES	1
Nelson, PS	1
Kantoff, PW	1
Uno, Y	1
Zhou, H	1
Fang, Y	1
Xu, T	1
Ni, WJ	1
Shen, AZ	1
Meng, XM	1
Rahman, N	1
Basharat, Z	1
Yousuf, M	1
Castaldo, G	1
Rastrelli, L	1
Khan, H	1
Yamaya, M	1
Nishimura, H	1
Deng, X	1
Kikuchi, A	1
Nagatomi, R	1
Nitulescu, GM	1
Paunescu, H	1
Moschos, SA	1
Petrakis, D	1
Nitulescu, G	1
Ion, GND	1
Spandidos, DA	1
Nikolouzakis, TK	1
Drakoulis, N	1
Tsatsakis, A	1
Yamamoto, M	1
Kiso, M	1
Sakai-Tagawa, Y	1
Iwatsuki-Horimoto, K	1
Imai, M	1
Takeda, M	1
Kinoshita, N	1
Ohmagari, N	1
Gohda, J	1
Semba, K	1
Matsuda, Z	1
Kawaguchi, Y	1
Kawaoka, Y	1
Inoue, JI	1
Giovane, RA	1
Rezai, S	1
Cleland, E	1
Henderson, CE	1
Mollica, V	1
Rizzo, A	1
Massari, F	1
Kishk, SM	1
Kishk, RM	1
Yassen, ASA	1
Nafie, MS	1
Nemr, NA	1
ElMasry, G	1
Al-Rejaie, S	1
Simons, C	1
Shirato, K	1
Kawase, M	1
Matsuyama, S	1
Zhou, Y	1
Vedantham, P	1
Lu, K	1
Agudelo, J	1
Carrion, R	1
Nunneley, JW	1
Barnard, D	1
McKerrow, JH	1
Renslo, AR	1
Simmons, G	1

Clinical Trials (21)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Novel Nasal Treatment for COVID-19[NCT05799521]	Phase 2	40 participants (Anticipated)	Interventional	2023-06-27	Recruiting
CORONA: A Phase 1/2 Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19[NCT04378244]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2022-12-12	Withdrawn (stopped due to Lack of Funding)
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.[NCT04480593]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2020-06-02	Completed
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).[NCT04632732]		140 participants (Actual)	Observational [Patient Registry]	2020-10-26	Completed
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349]	Early Phase 1	214 participants (Anticipated)	Interventional	2021-02-01	Enrolling by invitation
Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients[NCT04530617]	Phase 2	246 participants (Actual)	Interventional	2020-10-05	Terminated (stopped due to Results from the interim analysis)
Pilot Study on Peripheral Vascular Function in Covid-19 Patient[NCT04625036]		22 participants (Actual)	Observational [Patient Registry]	2020-05-30	Completed
The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009]		152 participants (Actual)	Interventional	2020-03-31	Completed
Pilot Phase II Randomized, Placebo-Controlled Clinical Trial for the Prevention and Progression of SARS-CoV-2 Infection of Subjects and Patients Using a Supplement Treatment With Carnipure Tartrate ( LCLT)[NCT05446961]	Phase 2	224 participants (Actual)	Interventional	2021-03-01	Completed
The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial[NCT04800224]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2021-04-12	Completed
Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial[NCT04418128]	Phase 2/Phase 3	84 participants (Anticipated)	Interventional	2020-06-10	Not yet recruiting
A Phase I/III Randomized, Double Blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre Exposure Prophylaxis of COVID 19 in Participants With Conditions Causing Immune Impairment. Sub-study: Phase II Open Label S[NCT05648110]	Phase 2/Phase 3	4,038 participants (Actual)	Interventional	2022-12-16	Active, not recruiting
Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial[NCT04466670]	Phase 2	379 participants (Anticipated)	Interventional	2020-07-11	Recruiting
Impact of the Genetic Polymorphism on the Severity of COVID-19 Infection in Egyptian Patients[NCT05157217]		98 participants (Anticipated)	Observational	2021-12-15	Recruiting
Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine[NCT05205746]	Phase 2	158 participants (Actual)	Interventional	2021-11-23	Completed
Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2[NCT05710783]	Phase 2/Phase 3	4,065 participants (Actual)	Interventional	2022-11-09	Completed
A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19[NCT04362059]		20 participants (Actual)	Interventional	2020-06-18	Completed
RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)[NCT04352400]	Phase 2/Phase 3	256 participants (Anticipated)	Interventional	2021-06-04	Recruiting
Detection Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Male Genitourinary System and Its Impact on Male Reproductive Health: an Observational Clinical Study.[NCT04388631]		200 participants (Anticipated)	Observational [Patient Registry]	2020-05-10	Recruiting
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction[NCT05184192]	Phase 2	50 participants (Anticipated)	Interventional	2022-01-10	Enrolling by invitation
Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia[NCT04420260]		152 participants (Actual)	Interventional	2021-03-18	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-Cause Death

(NCT04338009)
Timeframe: Up to 28 days

Intervention	Participants (Count of Participants)
Discontinuation Arm	10
Continuation Arm	11

AUC SOFA

"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days

Intervention	units on a scale (SOFA x days) (Median)
Discontinuation Arm	7
Continuation Arm	12

Hierarchical Composite Endpoint

"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days

Intervention	score on a scale (range 1 to 152) (Median)
Discontinuation Arm	81
Continuation Arm	73

Hypotension Requiring Vasopressors, Inotropes or Mechanical Hemodynamic Support

Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days

Intervention	Participants (Count of Participants)
Discontinuation Arm	8
Continuation Arm	9

Intensive Care Unit Admission or Respiratory Failure Requiring Mechanical Ventilation.

Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days

Intervention	Participants (Count of Participants)
Discontinuation Arm	14
Continuation Arm	16

Length of Hospital Stay

This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days

Intervention	days (Median)
Discontinuation Arm	5
Continuation Arm	6

Length of ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation

(NCT04338009)
Timeframe: Up to 28 days

Intervention	days (Median)
Discontinuation Arm	15
Continuation Arm	13

Reviews

4 reviews available for gabexate and Coronavirus Infections

Article	Year
Cancer discovery, 2020, Volume: 10, Issue:6 Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Esters; Female; Gabexate; Gene Expression Regulat	2020
Potential therapeutic targets and promising drugs for combating SARS-CoV-2. British journal of pharmacology, 2020, Volume: 177, Issue:14 Topics: Adenosine Monophosphate; Alanine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting En	2020
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review). International journal of molecular medicine, 2020, Volume: 46, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Betacoronavirus; Bromhexin	2020
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in medical virology, 2020, Volume: 30, Issue:5 Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized	2020

Other Studies

10 other studies available for gabexate and Coronavirus Infections

Article	Year
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 04-16, Volume: 181, Issue:2 Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V	2020
Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2? Science immunology, 2020, 04-03, Volume: 5, Issue:46 Topics: Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavir	2020
Camostat mesilate therapy for COVID-19. Internal and emergency medicine, 2020, Volume: 15, Issue:8 Topics: Animals; Coronavirus Infections; COVID-19; Disease Models, Animal; Esters; Gabexate; Guanidines; Jap	2020
Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2). Molecules (Basel, Switzerland), 2020, May-12, Volume: 25, Issue:10 Topics: Amino Acid Sequence; Betacoronavirus; Catalytic Domain; Computer Simulation; Coronavirus Infections;	2020
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. The Tohoku journal of experimental medicine, 2020, Volume: 251, Issue:1 Topics: Antiviral Agents; Benzamidines; Betacoronavirus; Cells, Cultured; Coronavirus 229E, Human; Coronavir	2020
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. Viruses, 2020, 06-10, Volume: 12, Issue:6 Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticoagulants;	2020
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future oncology (London, England), 2020, Volume: 16, Issue:27 Topics: Androgens; Angiotensin-Converting Enzyme 2; Betacoronavirus; Carcinogenesis; Coronavirus Infections;	2020
Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies. Molecules (Basel, Switzerland), 2020, Oct-29, Volume: 25, Issue:21 Topics: Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Esters; Gabexate;	2020
Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. Journal of virology, 2013, Volume: 87, Issue:23 Topics: Antiviral Agents; Cell Line; Cell Membrane; Coronavirus; Coronavirus Infections; Esters; Gabexate; G	2013
Protease inhibitors targeting coronavirus and filovirus entry. Antiviral research, 2015, Volume: 116 Topics: Animals; Antiviral Agents; Cathepsins; Cell Line, Tumor; Coronavirus; Coronavirus Infections; Dipept	2015